Salarius is an oncology based biotechnology company developing targeted treatments for patients who need them the most

Select Publications 

 

 

 

Select Publications about SP-2577 and analogs:

High-throughput virtual screening identifies novel N′-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.

2013 Journal of medicinal chemistry

 

Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells.

2012 Blood

 

Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma.

2014 AACR

 

Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration-and docetaxel-resistant prostate cancer cells.

2016 Prostate cancer and prostatic diseases

 

Select publications about LSD1’s role in cancer:

Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and-independent manners.

2012 ACS chemical biology

 

Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase

2011 Cancer cell

 

GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1

2016 Biochemical Journal

 

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

2005 Nature

 

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting

2016 Oncotarget

 

The histone LSD1 demethylase in stemness and cancer transcription programs

2013 Biochimica et Biophysica Acta

 

Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells

2016 Cancer Science

© 2017 Salarius Pharmaceuticals LLC.  All Rights Reserved.

 

   2450 Holcombe Boulevard, Suite J-608, Houston TX 77021